NCT06498167View on ClinicalTrials.gov

Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)

RecruitingOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

October 31, 2024

Study Completion Date

December 31, 2024

Conditions
Inflammatory DiseaseDrug Side EffectDrug UseAdverse Drug EventAdverse Drug ReactionSafety Issues
Interventions
DRUG

Upadacitinib

Exposure to upadacitinib (Rinvoq™) in its different formulations approved by the Portuguese regulatory authority (15, 30, or 45mg extended-release tablets).

Trial Locations (3)

4050-366

ACTIVE_NOT_RECRUITING

Unidade Local de Saúde de Santo António, E.P.E., Porto

4200-319

RECRUITING

Unidade Local de Saúde de São João, E.P.E., Porto

4434-502

ACTIVE_NOT_RECRUITING

Unidade Local de Saúde de Gaia/Espinho, E.P.E., Porto

All Listed Sponsors
collaborator

INFARMED - Autoridade Nacional do Medicamento e Produtos de Saúde, I.P.

UNKNOWN

collaborator

Unidade de Farmacovigilância do Porto

UNKNOWN

collaborator

Unidade Local de Saúde de São João, E.P.E.

UNKNOWN

collaborator

Unidade Local de Saúde de Santo António, E.P.E.

UNKNOWN

collaborator

Unidade Local de Saude de Gaia e Espinho EPE

OTHER

collaborator

RISE Health

UNKNOWN

lead

Universidade do Porto

OTHER